AZN - Understanding AstraZeneca's Position In Pharmaceuticals Industry Compared To Competitors | Benzinga
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating AstraZeneca (NASDAQ:AZN) and its primary competitors in the Pharmaceuticals industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.
AstraZeneca Background
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.
| Company | P/E | P/B | P/S | ROE | EBITDA (in billions) | Gross Profit (in billions) | Revenue Growth |
|---|---|---|---|---|---|---|---|
| AstraZeneca PLC | |||||||
| 34.10 | |||||||
| 5.58 | |||||||
| 4.72 | |||||||
| 4.97% | |||||||
| $3.79 | |||||||
| $9.46 | |||||||
| 5.99% | |||||||
| Eli Lilly and Co | |||||||
| 84.85 | |||||||
| 52.27 | |||||||
| 18.66 | |||||||
| 15.85% | |||||||
| $2.58 | |||||||
| $6.5 | |||||||
| 28.12% | |||||||
| Novo Nordisk A/S | |||||||
| 48.17 | |||||||
| 35.44 | |||||||
| 16.09 | |||||||
| 22.81% | |||||||
| $26.71 | |||||||
| $46.44 | |||||||
| 31.59% | |||||||
| Johnson & Johnson | |||||||
| 31.82 | |||||||
| 5.03 | |||||||
| 4.24 | |||||||
| 7.05% | |||||||
| $9.04 | |||||||
| $17.32 | |||||||
| 6.29% | |||||||
| Merck & Co Inc | |||||||
| 85.25 | |||||||
| 6.82 | |||||||
| 4.54 | |||||||
| -13.97% | |||||||
| $-4.16 | |||||||
| $11.01 | |||||||
| 3.03% | |||||||
| Novartis AG | |||||||
| 27.01 | |||||||
| 3.88 | |||||||
| 3.92 | |||||||
| 4.46% | |||||||
| $4.82 | |||||||
| $9.6 | |||||||
| 6.5% | |||||||
| Pfizer Inc | |||||||
| 8.54 | |||||||
| 1.83 | |||||||
| 2.36 | |||||||
| 2.33% | |||||||
| $4.35 | |||||||
| $9.5 | |||||||
| -54.1% | |||||||
| Sanofi SA | |||||||
| 14.98 | |||||||
| 1.77 | |||||||
| 2.78 | |||||||
| 1.98% | |||||||
| $2.53 | |||||||
| $7.41 | |||||||
| -0.56% | |||||||
| Bristol-Myers Squibb Co | |||||||
| 15.02 | |||||||
| 3.69 | |||||||
| 2.65 | |||||||
| 6.5% | |||||||
| $4.57 | |||||||
| $8.35 | |||||||
| -5.56% | |||||||
| Zoetis Inc | |||||||
| 36.71 | |||||||
| 17.36 | |||||||
| 9.88 | |||||||
| 14.72% | |||||||
| $1.05 | |||||||
| $1.57 | |||||||
| 6.24% | |||||||
| GSK PLC | |||||||
| 11.75 | |||||||
| 4.81 | |||||||
| 2.08 | |||||||
| 13.25% | |||||||
| $2.62 | |||||||
| $5.25 | |||||||
| 3.59% | |||||||
| Takeda Pharmaceutical Co Ltd | |||||||
| 23.57 | |||||||
| 1.01 | |||||||
| 1.73 | |||||||
| 1.35% | |||||||
| $366.11 | |||||||
| $737.5 | |||||||
| 8.86% | |||||||
| Viatris Inc | |||||||
| 6.10 | |||||||
| 0.54 | |||||||
| 0.72 | |||||||
| 1.26% | |||||||
| $1.16 | |||||||
| $1.61 | |||||||
| -4.81% | |||||||
| Dr Reddy's Laboratories Ltd | |||||||
| 19.49 | |||||||
| 3.75 | |||||||
| 3.52 | |||||||
| 5.89% | |||||||
| $22.4 | |||||||
| $39.55 | |||||||
| 29.2% | |||||||
| Corcept Therapeutics Inc | |||||||
| 34.02 | |||||||
| 6.70 | |||||||
| 7.38 | |||||||
| 5.75% | |||||||
| $0.03 | |||||||
| $0.12 | |||||||
| 13.86% | |||||||
| Average | |||||||
| 31.95 | |||||||
| 10.35 | |||||||
| 5.75 | |||||||
| 6.37% | |||||||
| $31.7 | |||||||
| $64.41 | |||||||
| 5.16% |